TNF and autoimmune disease: However, it has been shown that anti‐TNF‐α agents, especially adalimumab and infliximab (95), may exacerbate established vitiligo and induce new-onset vitiligo during treatment of other autoimmune diseases, including AS (96), Crohn’s disease (97), ulcerative colitis (98), psoriasis (99), and RA (100).